linezolid

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Burns

Conditions

Burns

Trial Timeline

May 1, 2006 → Jan 1, 2007

NCT ID

NCT00255996

About linezolid

linezolid is a phase 1 stage product being developed by Pfizer for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT00255996. Target conditions include Burns.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01805284	Approved	Completed	Feb 1, 2013	Sep 30, 2016	Pneumonia
NCT01040585	Pre-clinical	Withdrawn	Jul 1, 2010	Mar 1, 2011	Ventilator Acquired Pneumonia
NCT00255996	Phase 1	Completed	May 1, 2006	Jan 1, 2007	Burns
NCT01564758	Pre-clinical	Completed	Feb 1, 2004	Mar 1, 2005	Gram-Positive Bacterial Infections
NCT00147511	Approved	Completed	Jun 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00150332	Phase 3	Completed	Jan 1, 2003	Jan 1, 2006	Infections, Nosocomial

Competing Products

12 competing products in Burns

See all competitors

Product	Company	Stage	Hype Score
R-Pdf/Gbb 0.01% gel	Johnson & Johnson	Phase 2	52
Ceftolozane/tazobactam	Merck	Approved	85
Somatropin + 0.09% Saline Solution	Pfizer	Phase 2/3	64
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)	Bayer	Phase 3	74
cP12	United Therapeutics	Phase 2	49
cNP8	United Therapeutics	Phase 1	30
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications	Viatris	Approved	82
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin	Baxter	Phase 1/2	38
I-020502	Baxter	Phase 2	49
Pathogen-Reduced Plasma + Crystalloid Solutions	Cerus	Approved	77
NexoBrid + Gel Vehicle	MediWound	Phase 3	69
NexoBrid	MediWound	Phase 3	69

Other Products from Pfizer